"R&D productivity is declining, don't let anyone tell you otherwise," declared Robert Ruffolo, PhD, president of R&D at Wyeth 's pharmaceuticals division, during this year's Pharmaceutical Strategic Alliances conference. All Big Pharma agree that the R&D crisis exists, but their approaches to dealing with it vary.
For Wyeth, it's a numbers game; Novartis AG is talking about an entirely new drug discovery grammar.